• Revlon (NYSE:REV) is likely to report earnings for its first quarter.
• Bluegreen Vacations (NYSE:BVH) is expected to report earnings for its first quarter.
• TG Therapeutics (NASDAQ:TGTX) is expected to report earnings for its first quarter.
• Inspired Entertainment (NASDAQ:INSE) is likely to report earnings for its first quarter.
• NAPCO Security (NASDAQ:NSSC) is expected to report earnings for its third quarter.
• US Global Investors (NASDAQ:GROW) is projected to report earnings for its third quarter.
• Ambac Financial Group (NYSE:AMBC) is estimated to report quarterly loss at $0.53 per share on revenue of $53.50 million.
• Village Farms Intl (NASDAQ:VFF) is projected to report earnings for its first quarter.
Share this article
Share this article
ResearchAndMarkets.com s offering.
This report offers strategic insights into the overall neurological diseases treatment market along with the market size and estimates for the duration 2019 to 2029. The said research study cover in-depth analysis of neurological treatment market segments based on type of drugs, diseases and different geographies further segmented by countries.
For the purpose of this study, the global neurological diseases treatment market is segmented on the basis of drug type into anticholinergic, antiepileptic, antipsychotic, hypnotic & sedative, analgesics, antihypertensive, anticoagulants, and others. Market size estimates and forecast for these segments for the period 2019 to 2029 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2021 to 2029, considering 2020 as the base year.
Markets
Leerink Partners analyst Marc Goodman maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) on April 26. The company’s shares closed last Wednesday at $59.74, close to its 52-week low of $50.05.
According to TipRanks.com, Goodman is a 3-star analyst with an average return of 3.2% and a 47.7% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Satsuma Pharmaceuticals.
Currently, the analyst consensus on Axsome Therapeutics is a Strong Buy with an average price target of $144.00, representing a 136.7% upside. In a report issued on April 26, Mizuho Securities also maintained a Buy rating on the stock with a $118.00 price target.
Inspire Medical Systems (INSP)
In a report issued on April 22, Michael Polark from Robert W. Baird maintained a Buy rating on Inspire Medical Systems, with a price target of $260.00. The company’s shares closed last Friday at $227.68, close to its 52-week high of $252.25.
According to TipRanks.com, Polark is a 4-star analyst with an average return of 17.3% and a 72.4% success rate. Polark covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Irhythm Technologies, and Intuitive Surgical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Inspire Medical Systems with a $257.00 average price target.
Leerink Partners Remains a Buy on Aldeyra Therapeutics (ALDX) analystratings.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from analystratings.com Daily Mail and Mail on Sunday newspapers.